Announcements
- Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
- Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma
- Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Tempest to Participate in Upcoming Investor Conferences
- Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
- Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
- Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
- Tempest Reports Year End 2023 Financial Results and Provides Business Update
- Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types
- Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
More ▼
Key statistics
As of last trade Tempest Therapeutics Inc (3OS:MUN) traded at 1.95, 5.97% above its 52-week low of 1.84, set on Jun 21, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.95 |
---|---|
High | 1.95 |
Low | 1.95 |
Bid | 1.85 |
Offer | 1.87 |
Previous close | 1.98 |
Average volume | 2.20k |
---|---|
Shares outstanding | 22.22m |
Free float | 22.20m |
P/E (TTM) | -- |
Market cap | 46.88m USD |
EPS (TTM) | -1.76 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 07:06 BST.
More ▼